Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.41 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 6/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630193 | 1.00 | HTR2C (0.41) | HTR2CHTR2AHTR2BKDM1AKDM1B | |
| SCHEMBL6711039 | 0.85 | HTR2C (0.56) | HTR2CHTR2AHTR2BNPC1RAB9A | |
| SCHEMBL6040717 | 0.81 | HTR2C (0.47) | HTR2CHTR2AHTR2BNPC1RAB9A | |
| SCHEMBL26122002 | 0.81 | HTR2C (0.37) | HTR2CHTR2AHTR2BKDM1ANPC1 | |
| SCHEMBL25385697 | 0.80 | APP (0.38) | NPC1RAB9AL3MBTL1MAPT | |
| SCHEMBL515378 | 0.80 | HTR2C (0.45) | HTR2CHTR2ANPC1RAB9APOLB | |
| SCHEMBL29654713 | 0.80 | HTR2C (0.45) | HTR2CHTR2ANPC1RAB9APOLB | |
| SCHEMBL16056077 | 0.76 | HTR2C (0.38) | HTR2CHTR2ANPC1RAB9APOLB | |
| SCHEMBL21408540 | 0.75 | KDM1A (0.43) | KDM1AKDM1BKCNH2 | |
| SCHEMBL25648840 | 0.75 | ALDH1A1 (0.37) | HTR2CHTR2ARAB9APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HTR2C 3843/4885HTR2A 2838/4885HTR2B 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.